undamentalytics Newsletter
Sign in

Neurocrine Biosciences Inc balance sheet

At the end of fiscal 2025, Neurocrine Biosciences Inc had total assets of $4.63bn, total liabilities of $1.38bn and shareholders' equity of $3.25bn. It held $713m in cash against $0 of debt: net cash of $713m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents3754506445317483255142112187341263251233713642
Receivables—42143——03157127157186350439479687957
Inventory———————01111728313538576966
Total current assets—1331321891481983843105557388311,0169731,4541,6071,7252,5232,008
Goodwill————————————05666501
Total assets—1441381961552434753658189931,3061,7352,0732,3693,2513,7194,6325,627
Accounts payable—1110035614————————
Deferred revenue (current)—37343——————————————
Total current liabilities—534716121626305488565187246538655508743985
Total debt00000000370388409318335169—000
Total liabilities—1257842343450504455126696096996611,0191,1291,3781,749
Shareholders' equity419601541202094243153724816371,1261,3741,7082,2322,5903,2533,879
Net debt (negative = net cash)−37−54−50−64−45−31−74−83115247297131−6−94−251−233−713−642
Shares outstanding—55m55m66m67m76m86m87m89m91m92m94m95m97m99m99m100m101m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BMRN vs NBIXARGX vs NBIXBNTX vs NBIX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Neurocrine Biosciences Inc's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neurocrine Biosciences Inc.